These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 4175472)
1. Observations against a causal relationship between the long-acting thyroid stimulator and ophthalmopathy in Graves' disease. McKenzie JM; McCullagh EP J Clin Endocrinol Metab; 1968 Aug; 28(8):1177-82. PubMed ID: 4175472 [No Abstract] [Full Text] [Related]
3. Large doses of radioiodide in Graves' disease: effect on ophthalmopathy and long-acting thyroid stimulator. Pequegnat EP; Mayberry WE; McConahey WM; Wyse EP Mayo Clin Proc; 1967 Dec; 42(12):802-11. PubMed ID: 4169552 [No Abstract] [Full Text] [Related]
4. The long-acting thyroid stimulator and the result of I 131 treatment for thyrotoxicosis. Martin FI; Larkins RG; Alford FP; Andrews JT; Greenberg PB; Melick RA; Penington JS Aust N Z J Med; 1972 May; 2(2):168-72. PubMed ID: 4116447 [No Abstract] [Full Text] [Related]
5. Does LATS cause hyperthyroidism in Graves' disease? (A review biased toward the affirmative). McKenzie JM Metabolism; 1972 Sep; 21(9):883-94. PubMed ID: 4115791 [No Abstract] [Full Text] [Related]
6. [The long acting thyroid stimulator (LATS) in some thyroid diseases. Preliminary results]. Busnardo B; Accordi F; Debiasi S Acta Isot (Padova); 1968 Oct; 8(2):165-79. PubMed ID: 5761578 [No Abstract] [Full Text] [Related]
7. The effect of radioablation of the thyroid gland in Graves' disease with high levels of long-acting thyroid stimulator (LATS). Volpé R; Desbarats-Schonbaum ML; Schonbaum E; Row VV; Ezrin C Am J Med; 1969 Feb; 46(2):217-26. PubMed ID: 5818477 [No Abstract] [Full Text] [Related]
8. [The determination of long-acting thyroid stimulator (LATS) in thyroid diseases]. Depisch D; Höfer R; Schatz H Wien Z Inn Med; 1968; 49(4):121-30. PubMed ID: 5757238 [No Abstract] [Full Text] [Related]
9. Diagnosis of Graves' ophthalmopathy without hyperthyroidism: long-acting thyroid stimulator (LATS) determination as laboratory adjunct. Gharib H; Mayberry WE Mayo Clin Proc; 1970 Jun; 45(6):444-9. PubMed ID: 4193249 [No Abstract] [Full Text] [Related]
10. The long-acting thyroid stimulatory: is it of importance in Graves' disease. McKenzie JM; Zakarija M; D'Amour P; Joasoo A N Z Med J; 1975 Jan; 81(531):18-21. PubMed ID: 165442 [No Abstract] [Full Text] [Related]
11. Studies on the pathogenesis of the ophthalmopathy of Graves' disease. Kriss JP; Pleshakov V; Rosenblum AL; Holderness M; Sharp G; Utiger R J Clin Endocrinol Metab; 1967 Apr; 27(4):582-93. PubMed ID: 6071430 [No Abstract] [Full Text] [Related]
17. Familial incidence of long-acting thyroid stimulator (LATS) in Graves' disease. Bonnyns M; Vanhaelst L Horm Metab Res; 1972 Mar; 4(2):132. PubMed ID: 5067566 [No Abstract] [Full Text] [Related]
18. [Long-acting thyroid stimulator (LATS), thyrotropin (TSH) and the pathogenesis of hyperthyroidism]. Lamberg BA; Gordin A Nord Med; 1968 Dec; 80(49):1651-7. PubMed ID: 5757398 [No Abstract] [Full Text] [Related]
19. [Effect of iodine administration on the thyrotropic hormone and long-acting thyroid stimulator level in the plasma]. Földes J; Krasznai I; Piroska E; Gesztesi E; Takács I Endokrinologie; 1967; 52(1):80-7. PubMed ID: 4171706 [No Abstract] [Full Text] [Related]
20. Long-acting thyroid stimulator (LATS) in toxic nodular goitre, toxic adenoma and Graves' disease. Lamberg BA; Gordin A; Viherkoski M; Kvist G Acta Endocrinol (Copenh); 1969 Oct; 62(2):199-209. PubMed ID: 5394703 [No Abstract] [Full Text] [Related] [Next] [New Search]